Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Income from Continuing Operations (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Income from Continuing Operations data on record, last reported at 35558000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 17.47% year-over-year to 35558000.0; the TTM value through Sep 2025 reached 97786000.0, down 25.68%, while the annual FY2024 figure was 68419000.0, 43.88% down from the prior year.
  • Income from Continuing Operations reached 35558000.0 in Q3 2025 per ABEO's latest filing, down from 23749000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 8295000.0 in Q2 2022 and bottomed at 46669000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 18683473.68, with a median of 15545000.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: surged 71.9% in 2022, then crashed 164.61% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 46669000.0 in 2021, then soared by 71.9% to 13114000.0 in 2022, then decreased by 1.56% to 13318000.0 in 2023, then crashed by 33.31% to 17754000.0 in 2024, then tumbled by 100.28% to 35558000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 35558000.0 in Q3 2025, 23749000.0 in Q2 2025, and 20725000.0 in Q1 2025.